The lead program, ELI-002 7P, is a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC). However, the Phase 2 AMPLIFY-7P study did not meet the pre-specified primary endpoint of disease-free survival (DFS) in the intent-to-treat population (June 15, 2026). The company's cash runway is expected to extend into Q4 2026, beyond the anticipated DFS readout.
Cyborg Score Rationale
Elicio has a scientifically promising AMP technology platform with peer-reviewed validation (April 2026 Science Advances publication), but critically, the Phase 2 AMPLIFY-7P trial failed to meet its primary DFS endpoint (June 15, 2026). This represents a major setback for the lead program. However, the company retains cash runway into Q4 2026 to pursue next steps and evaluate additional development strategies.
Top Insights
(June 15, 2026) Phase 2 AMPLIFY-7P study failed to meet primary DFS endpoint in intent-to-treat population—major setback for lead program ELI-002 7P
(April 30, 2026) AMP-DNA adjuvant technology validated in peer-reviewed Science Advances publication, demonstrating robust T cell activation and durable immune memory
(May 11, 2026) Cash position extends into Q4 2026, providing runway to execute refined Phase 3 strategy and explore next-generation development paths
ELI-002 7P targets 88% of PDAC patients and 25% of all solid tumors, positioning it for broad clinical utility if efficacy can be demonstrated
Named Competitors
Checkpoint Inhibitors — Anti-PD-1/PD-L1 immunotherapies for PDAC and mKRAS cancers
KRAS-Targeted Therapies — Direct KRAS mutation inhibitors and combination therapies for mKRAS-driven cancers
Personalized Cancer Immunotherapy — Off-the-shelf and personalized neoantigen-targeting immunotherapies
Recent Developments
(June 15, 2026) Phase 2 AMPLIFY-7P trial did not meet primary DFS endpoint; company outlines refined Phase 3 development strategy
(April 30, 2026) Peer-reviewed publication in Science Advances highlighting potent and durable immune responses from AMP-DNA technology
(May 11, 2026) Q1 2026 earnings reported; cash runway extended into Q4 2026 with EPS of -$0.65
(April 16, 2026) Granted 21,210 inducement stock options to new employee at $11.78 per share
Open the full interactive Elicio Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.